Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma

Journal of Endocrinological Investigation

Volumn 27, Issue 11, 2004, Pages 1055-1059

  Miyoshi, T ^a   Otsuka, F ^a   Takeda, M ^a   Inagaki, K ^a   Suzuki, J ^a   Ogura, T ^a   Date, I ^a   Hashimoto, K ^b   Makino, H ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KOCHI UNIVERSITY   (Japan)

Author keywords

ACTH; Cabergoline; Cushing's disease; Dopamine D2 receptor; Gel filtration analysis; Pituitary adenoma

Indexed keywords

CABERGOLINE; CORTICOTROPIN; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE;

ADENOMA; ARTICLE; CASE REPORT; CUSHING DISEASE; HUMAN; HYPOPHYSIS TUMOR; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SECRETION; TREATMENT OUTCOME;

ADENOMA; ADRENOCORTICOTROPIC HORMONE; DOPAMINE AGONISTS; ERGOLINES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; RECEPTORS, DOPAMINE D2; TREATMENT OUTCOME;

EID: 15744390731     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03345309     Document Type: Article

References (17)

1. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992, 13: 220-40.
2. Selvais P, Donckier J, Buysschaert M, Maiter D. Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas. Eur J Endocrinol 1998, 138: 153-9.
3. Katznelson L, Bogan JS, Trob JR, et al. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 1998, 83: 1619-23.
4. Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med 1988, 109: 487-93.
5. Shimon I, Melmed S. Management of pituitary tumors. Ann Intern Med 1998, 129: 472-83.
6. Hashimoto K, Kaneda T, Nagano I, Asaba K, Takeda K, Takao T. Pituitary adenoma showing intermittent secretion of high molecular weight adrenocorticotropin without evidenice of Cushing's disease. Horm Res 1999, 52: 39-44.
7. Takeda M, Otsuka F, Suzuki J, et al. Involvement of activin/BMP system in development of human pituitary gonadotropinomas and nonfunctioning adenomas. Biochem Biophys Res Commun 2003, 306: 812-8.
8. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994, 331: 904-9.
9. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999, 84: 2518-22.
10. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998, 83: 374-8.
11. T'Sjoen G, Defeyter I, Van De Saffele J, Rubens R, Vandeweghe M. Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline. J Endocrinol Invest 2002, 25: 172-5.
12. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 1999, 22: 860-5.
13. Petrossians P, Ronci N, Valdes Socin H, et al. ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol 2001, 144: 51-7.
14. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001, 22: 724-63.
15. Renner U, Arzberger T, Pagotto U, et al. Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1998, 83: 1368-75.
16. Murata Y, Ando H, Nagasaka T, et al. Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma. J Clin Endocrinol Metab 2003, 88: 1988-93.
17. Saiardi A, Borrelli E. Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice. Mol Endocrinol 1998, 12: 1133-9.